Skip to menu Skip to content Skip to footer

2007

Journal Article

Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders

Gandhi, M., Wilkie, G. M., Dua, U., Mollee, P., Grimmett, K., Williams, T., Whitaker, N., Gill, D. and Crawford, D. (2007). Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders. American Journal of Transplantation, 7 (5), 1293-1299. doi: 10.1111/j.1600-6143.2007.01796.x

Immunity, homing and efficacy of allogeneic adoptive immunotherapy for posttransplant lymphoproliferative disorders

2007

Journal Article

Epstein-Barr virus T-cell immunity despite rituximab

Nehring, Angela K., Dua, Ujjwal, Mollee, Peter, Gill, Devinder, Grimmett, Karen, Khanna, Rajiv, Moss, Denis and Gandhi, Maher K. (2007). Epstein-Barr virus T-cell immunity despite rituximab. British Journal of Haematology, 136 (4), 628-632. doi: 10.1111/j.1365-2141.2006.06482.x

Epstein-Barr virus T-cell immunity despite rituximab

2007

Journal Article

Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases

Tate, Jillian R., Mollee, Peter, Dimeski, Goce, Carter, Andrew C. and Gill, Devinder (2007). Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. Clinica Chimica Acta, 376 (1-2), 30-36. doi: 10.1016/j.cca.2006.07.011

Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases

2007

Journal Article

The International Prognostic Index: the “gold-standard” in post-transplant lymphoproliferative disorders after renal transplantation

Hourigan, M. J., Mollee, P. N., Gill, D. S., Doecke, J., Norris, D., Johnson, D. W. and Gandhi, M. K.. (2007). The International Prognostic Index: the “gold-standard” in post-transplant lymphoproliferative disorders after renal transplantation. American Journal of Transplantation, 7, 399-399.

The International Prognostic Index: the “gold-standard” in post-transplant lymphoproliferative disorders after renal transplantation

2006

Journal Article

Increased Mortality with FLA Compared with ADE Chemotherapy in High-risk AML (Letter to the Editor)

Lane, Steven W., Marlton, Paula and Mollee, Peter N. (2006). Increased Mortality with FLA Compared with ADE Chemotherapy in High-risk AML (Letter to the Editor). Blood, 108 (12), 3950-3951. doi: 10.1182/blood-2006-06-032680

Increased Mortality with FLA Compared with ADE Chemotherapy in High-risk AML (Letter to the Editor)

2006

Journal Article

Characterisation and prognostic significance of WT-1 gene expression in acute myeloid leukemia (AML)

Lane, Steven W., Saal, Russell, Negus, Suzanne, Mollee, Peter, Mather, M., Gill, Devinder, Mills, Anthony K., Bird, Robert J., Hourigan, Matthew J., Jones, Mark and Marlton, Paula (2006). Characterisation and prognostic significance of WT-1 gene expression in acute myeloid leukemia (AML). Blood, 108 (11). doi: 10.1182/blood.v108.11.2313.2313

Characterisation and prognostic significance of WT-1 gene expression in acute myeloid leukemia (AML)

2006

Journal Article

The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization

Keane, Colm, Gibbs, Simon, Seymour, John F., Mills, Anthony K ., Grimmett, Karen, Van Kuilenberg, Rosita, Russell, Saal, Gill, Devinder, Prince, H. Miles, Marlton, Paula and Mollee, Peter (2006). The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization. Hematological Oncology, 24 (3), 159-163. doi: 10.1002/hon.784

The Hyper-CVAD chemotherapy regimen has an adverse long-term impact on the ability to mobilize peripheral blood stem cells, which can be readily circumvented by using the early cycles for mobilization

2006

Journal Article

Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF)supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy

Lane, Steven W., Crawford, Julie, Kenealy, Melita, Cull, Gavin, Seymour, John F., Prince, H. Miles, Marlton, Paula, Gill, Devinder ‌ and Mollee, Peter‌ N. (2006). Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF)supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy. Leukemia and Lymphoma, 47 (9), 1813-1817. doi: 10.1080/10428190600632832

Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF)supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy

2006

Journal Article

The effect of the Hyper-CVAD chemotherapy regimen on fertility and ovarian function

Seshadri, T., Hourigan, M. J., Wolf, M., Mollee, P. N. and Seymour, J. F. (2006). The effect of the Hyper-CVAD chemotherapy regimen on fertility and ovarian function. Leukemia Research, 30 (4), 483-485. doi: 10.1016/j.leukres.2005.08.014

The effect of the Hyper-CVAD chemotherapy regimen on fertility and ovarian function

2006

Journal Article

A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma

Kuruvilla, John, Song, Kevin, Mollee, Peter, Panzarella, Tony, McCrae, Jan, Nagy, Tracy, Crump, Michael and Keating, Armand (2006). A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma. Hematology, 11 (1), 25-29. doi: 10.1080/10245330500276592

A phase II study of thalidomide and vinblastine for palliative patients with Hodgkin's lymphoma

2006

Journal Article

Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma

Gandhi, M. K., Lambley, E., Burrows, J., Dua, U., Elliott, S., Shaw, P. J., Prince, H. M., Wolf, M., Clarke, K., Underhill, C., Mills, T., Mollee, P., Gill, D., Marlton, P., Seymour, J. F. and Khanna, R. (2006). Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma. Clinical Cancer Research, 12 (2), 460-464. doi: 10.1158/1078-0432.CCR-05-2008

Plasma Epstein-Barr virus (EBV) DNA is a biomarker for EBV-positive Hodgkin's lymphoma

2006

Journal Article

Hereditary fibrinogen A alpha-chain amyloidosis

Lane, S. W., Goodman, H. J., Francis, L., Bofinger, A. M. and Mollee, P. N. (2006). Hereditary fibrinogen A alpha-chain amyloidosis. Pathology, 38 (4), 380-382. doi: 10.1080/00313020600820823

Hereditary fibrinogen A alpha-chain amyloidosis

2006

Journal Article

Effects of hyperlipidemia on plasma sodium, potassium, and chloride measurements by an indirect ion-selective electrode measuring system

Dimeski, Goce, Mollee, Peter and Carter, Andrew (2006). Effects of hyperlipidemia on plasma sodium, potassium, and chloride measurements by an indirect ion-selective electrode measuring system. Clinical Chemistry, 52 (1), 155-156. doi: 10.1373/clinchem.2005.054981

Effects of hyperlipidemia on plasma sodium, potassium, and chloride measurements by an indirect ion-selective electrode measuring system

2005

Journal Article

Increased Lipid Concentration Is Associated with Increased Hemolysis

Dimeski, Goce, Mollee, Peter and Carter, Andrew (2005). Increased Lipid Concentration Is Associated with Increased Hemolysis. Clinical Chemistry, 51 (12), 2425-2425. doi: 10.1373/clinchem.2005.058644

Increased Lipid Concentration Is Associated with Increased Hemolysis

2005

Journal Article

Role of VAD in the initial treatment of multiple myeloma

Lane, Steven W., Gill, Devinder, Mollee, Peter N. and Rajkumar, S. Vincent (2005). Role of VAD in the initial treatment of multiple myeloma. Blood, 106 (10), 3674-3675. doi: 10.1182/blood-2005-07-2610

Role of VAD in the initial treatment of multiple myeloma

2005

Journal Article

The reporting of serum protein electrophoresis to clinicians

Tate, Jillian R., Mollee, Peter and Gill, Devinder (2005). The reporting of serum protein electrophoresis to clinicians. Clinica Chimica Acta, 358 (1-2), 204-205. doi: 10.1016/j.cccn.2005.04.010

The reporting of serum protein electrophoresis to clinicians

2005

Journal Article

Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission

Song, Kevin W., Mollee, Peter N., Hogge, Donna E., Gupta, Vikas, Bernett, Michael J., Forrest, Donna L., Lavoie, Julye C., Nevill, Thmas J., Nantel, Stephen H., Shepherd, John D., Smith, Clay A., Sutherland, Heather J., Toze, Cynthia L., Crump, Michael and Keating, Armand (2005). Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission. Leukemia and Lymphoma, 46 (4), 525-531. doi: 10.1080/10428190400025112

Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission

2005

Journal Article

Allogeneic stem cell transplantation for mantle cell lymphoma--does it deserve a better look?

Rifkind, Joshua, Mollee, Peter, Messner, Hans and Lipton, Jeffrey (2005). Allogeneic stem cell transplantation for mantle cell lymphoma--does it deserve a better look?. Leukemia & Lymphoma, 46 (2), 217-223. doi: 10.1080/10428190400015022

Allogeneic stem cell transplantation for mantle cell lymphoma--does it deserve a better look?

2005

Journal Article

Serum free light chains for monitoring multiple myeloma

Tate, J., Mollee, P. and Gill, D. (2005). Serum free light chains for monitoring multiple myeloma. British Journal of Haematology, 128 (3), 405-406. doi: 10.1111/j.1365-2141.2004.05338.x

Serum free light chains for monitoring multiple myeloma

2005

Journal Article

Stem cell transplantation for mantle cell lymphoma: if, when and how?

Kiss, T. L., Mollee, P., Lazarus, H. M. and Lipton, J. H. (2005). Stem cell transplantation for mantle cell lymphoma: if, when and how?. Bone Marrow Transplantation, 36 (8), 655-661. doi: 10.1038/sj.bmt.1705080

Stem cell transplantation for mantle cell lymphoma: if, when and how?